Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DME81IY)

Drug Name
Succimer Drug Info
Synonyms
Succimer; meso-2,3-Dimercaptosuccinic acid; 304-55-2; DMSA; (2R,3S)-rel-2,3-Dimercaptosuccinic acid; meso-Dimercaptosuccinic acid; Chemet; Dim-sa; Succimerum; Succimero; Dimercaptosuccinic acid; Succimerum [INN-Latin]; Succimero [INN-Spanish]; (R*,S*)-2,3-Dimercaptobutanedioic acid; Butanedioic acid, 2,3-dimercapto-, (2R,3S)-rel-; UNII-DX1U2629QE; Succimer [USAN:INN:BAN]; HSDB 6783; EINECS 206-155-2; Ro 1-7977; BRN 1725150; DX1U2629QE; CHEBI:63623; Butanedioic acid, 2,3-dimercapto-, (R*,S*)-; meso-2,3-Dimercaptobernsteinsaeure
Cross-matching ID
PubChem CID
2724354
ChEBI ID
CHEMBL1201073
CAS Number
CAS 304-55-2
TTD Drug ID
D01GYK
VARIDT Drug ID
DR01256
ACDINA Drug ID
D00640

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Citrate cycle (TCA cycle) 1.93 3.34e-2 30/30 (100%) DLD;IDH3A;ACO2;...
Ribosome biogenesis in eukaryotes 1.85 3.34e-2 52/108 (48.15%) POP5;DROSHA;CSNK2A2;...
Alanine, aspartate and glutamate metabolism -1.62 4.98e-2 27/37 (72.97%) GAD2;ABAT;AGXT;...
D-Glutamine and D-glutamate metabolism -1.67 4.96e-2 5/5 (100%) GLUD1;GLS2;GLUD2;...
Antigen processing and presentation -1.70 4.49e-2 60/78 (76.92%) HSPA1L;CALR;HLA-E;...
PD-L1 expression and PD-1 checkpoint pathway in cancer -1.71 4.41e-2 79/89 (88.76%) ZAP70;LCK;MAP2K3;...
Pentose and glucuronate interconversions -1.73 4.14e-2 17/34 (50%) UGT2B4;AKR1A1;DCXR;...
Complement and coagulation cascades -1.73 4.40e-2 76/85 (89.41%) CD55;F11;MBL2;...
IL-17 signaling pathway -1.75 3.37e-2 84/94 (89.36%) CCL20;NFKBIA;TRAF4;...
p53 signaling pathway -1.79 2.36e-2 63/73 (86.3%) GADD45A;CDK6;CCNG1;...
Leishmaniasis -1.80 1.87e-2 67/77 (87.01%) HLA-DQA1;PTPN6;NFKBIA;...
Epithelial cell signaling in Helicobacter pylori infect... -1.81 1.96e-2 62/70 (88.57%) NFKBIA;JUN;ATP6V0D1;...
NF-kappa B signaling pathway -1.83 1.44e-2 90/104 (86.54%) BIRC2;CARD10;ZAP70;...
Lipid and atherosclerosis -1.84 1.68e-2 190/215 (88.37%) PIK3R3;PTK2;NFKBIA;...
Arginine biosynthesis -1.85 1.57e-2 17/22 (77.27%) GLUD1;NOS3;GLS2;...
Fluid shear stress and atherosclerosis -1.90 1.12e-2 123/139 (88.49%) ITGA2B;SUMO1;TXN;...
Rheumatoid arthritis -1.92 1.12e-2 78/93 (83.87%) HLA-DQA1;CCL20;JUN;...
Malaria -1.95 1.12e-2 44/50 (88%) THBS3;TLR2;HGF;...
TNF signaling pathway -1.97 1.12e-2 103/112 (91.96%) PIK3R3;CCL20;NFKBIA;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 1.11uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 1.11uM - 10uM 6H, 24H